MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

3.95 -1

Buy Sell

Overview

Share price change

24h

Current

Min

3.87

Max

3.95

Key metrics
By Trading Economics
Income	466K -27M
Sales	2M 15M
Profit margin	-178.834
Employees	141
EBITDA	-2M -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+267.67% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	2.1M 231M
Previous open	4.95
Previous close	3.95

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 kwi 2026, 04:27 UTC

Major News Events

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3 kwi 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 kwi 2026, 18:30 UTC

Major News Events

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3 kwi 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3 kwi 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3 kwi 2026, 17:44 UTC

Acquisitions, Mergers, Takeovers

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3 kwi 2026, 16:50 UTC

Major News Events

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3 kwi 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 kwi 2026, 16:12 UTC

Earnings

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3 kwi 2026, 15:56 UTC

Market Talk

Major News Events

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3 kwi 2026, 15:56 UTC

Market Talk

Major News Events

Global Equities Roundup: Market Talk

3 kwi 2026, 15:56 UTC

Market Talk

Major News Events

Global Forex and Fixed Income Roundup: Market Talk

3 kwi 2026, 15:20 UTC

Major News Events

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3 kwi 2026, 15:08 UTC

Acquisitions, Mergers, Takeovers

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3 kwi 2026, 14:11 UTC

Market Talk

Major News Events

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3 kwi 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3 kwi 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 kwi 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3 kwi 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3 kwi 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3 kwi 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3 kwi 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3 kwi 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3 kwi 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

3 kwi 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 kwi 2026, 04:01 UTC

Market Talk

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3 kwi 2026, 02:01 UTC

Market Talk

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3 kwi 2026, 01:59 UTC

Market Talk

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3 kwi 2026, 01:44 UTC

Market Talk

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3 kwi 2026, 01:22 UTC

Market Talk

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

267.67% upside

12 Months Forecast

Average 14.67 USD 267.67%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.